Síndrome nefrótico como manifestación de microangiopatía trombótica secundaria al uso crónico de sunitinib

Nieto-Ríos, John Fredy; García-Prada, Camilo Andrés; Aristizabal-Alzate, Arbey; Zuluaga-Valencia, Gustavo; Cadavid-Aljure, Dahyana; Serna-Higuita, Lina Maria; Arias, Luis F.
Nefrología (Madrid) ; 42(6): 722-726, nov.-dic. 2022. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-212602

Documentos relacionados

  1. KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients.
  2. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
  3. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.
  4. Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
  5. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
  6. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.
  7. [Gastrointestinal Stromal Tumor of the Small Intestine with Dissemination Successfully Treated with Surgical Resection and Adjuvant Chemotherapy with Sunitinib-A Case Report].
  8. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
  9. A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
  10. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?